Clinical Trial Update: The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating whether a PET/CT imaging agent (18F-ALF-NOTA-PRGD2) can predict efficacy and adverse events of apatinib in various malignancie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cervical Cancer
• Esophageal Cancer
• Malignancies
• Non-small Cell Lung Cancer
• Ovary Cancer
• Stomach Cancer

Drugs mentioned

• Apatinib (apatinib)

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: Malignancies, Stomach Cancer | Phase 4 | Status: COMPLETED